{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T05:17:06Z","timestamp":1698643026798},"reference-count":26,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T00:00:00Z","timestamp":1362700800000},"content-version":"vor","delay-in-days":4602,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2000,8]]},"abstract":"<jats:p>This open\u2010label, single\u2010dose, crossover study was conducted to assess the effect of irbesartan on the pharmacokinetics of total simvastatin acid in 14 healthy subjects. Subjects were randomized to receive one simvastatin 40 mg tablet or one simvastatin 40 mg tablet + one irbesartan 300 mg tablet. Subjects were crossed over to the other treatment after a 7\u2010 to 10\u2010day washout period. Serum samples were collected at specified times before and over a 24\u2010hour period after dosing. Safety was assessed by monitoring vital signs, laboratory tests, and adverse events. Irbesartan did not exhibit a clinically significant effect on the peak serum concentration and area under the concentration versus time curve to infinity (AUC<jats:sub>0\u2010\u221e<\/jats:sub>) of total simvastatin acid. The mean AUC<jats:sub>0\u2010\u221e<\/jats:sub> of total simvastatin acid was 74.55 ng \u00d7 h\/mL when simvastatin was given alone and 67.55 ng \u00d7 h\/mL when simvastatin and irbesartan were given concomitantly. The time to peak serum concentration for both treatments was 3 hours. No serious adverse events occurred during the study, and both agents were well tolerated. In summary, irbesartan had no significant effect on the single\u2010dose pharmacokinetics of total simvastatin acid.<\/jats:p>","DOI":"10.1177\/00912700022009611","type":"journal-article","created":{"date-parts":[[2003,7,19]],"date-time":"2003-07-19T09:38:13Z","timestamp":1058607493000},"page":"875-879","source":"Crossref","is-referenced-by-count":18,"title":["Irbesartan Does Not Affect the Pharmacokinetics of Simvastatin in Healthy Subjects"],"prefix":"10.1002","volume":"40","author":[{"given":"Maria R.","family":"Marino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nimish N.","family":"Vachharajani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ophelia W.","family":"Hadjilambris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,8]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"826","article-title":"Pharmacological characterization of SR 47436, a new nonpeptide AT1 subtype angiotensin II receptorantagonist","volume":"265","author":"Cazaubon C","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_3_2","first-page":"818","volume-title":"Physician's Desk Reference.","year":"2000"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(97)00501-3"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.31.6.1311"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(98)00313-0"},{"key":"e_1_2_1_7_2","doi-asserted-by":"crossref","first-page":"258C","DOI":"10.1016\/S0735-1097(98)81559-3","article-title":"Rate and extent of left ventricular hypertrophy regression: a comparison of angiotensin II blockade with irbesartan and beta\u2010blockade (abstract)","volume":"31","author":"Kahan T","year":"1998","journal-title":"JACC"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/15.4.487"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(97)91087-6"},{"key":"e_1_2_1_10_2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1742-1241.2000.tb11833.x","article-title":"A study of the efficacy and safety of irbesartan in combination with conventional therapy, including ACE inhibitors, in heart failure. Irbesartan Heart Failure Group","volume":"54","author":"Tonkon M","year":"2000","journal-title":"Int J Clin Pract"},{"key":"e_1_2_1_11_2","doi-asserted-by":"crossref","first-page":"188A","DOI":"10.1016\/S0735-1097(98)80941-8","article-title":"Irbesartan compared with lisinopril in patients with mild to moderate heart failure (abstract)","volume":"31","author":"Vijay N","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(98)00695-0"},{"key":"e_1_2_1_13_2","first-page":"288","article-title":"Role of cytochrome P\u20104502C9 in irbesartan oxidation by human liver microsomes","volume":"27","author":"Bourri\u00e9 M","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_1_14_2","first-page":"1191","article-title":"In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s","volume":"25","author":"Prueksaritanont T","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_1_15_2","volume-title":"Guidance for Industry: In Vivo Drug Metabolism\/Drug Interaction Studies\u2014Study Design, Data Analysis, and Recommendations for Dosing and Labeling.","author":"Food and Drug Administration","year":"1998"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050094"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(98)90165-5"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(98)90151-5"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/bms.1200220102"},{"key":"e_1_2_1_20_2","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1201\/b14095","volume-title":"Pharmacokinetics","author":"Gibaldi M","year":"1982"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01059549"},{"key":"e_1_2_1_22_2","volume-title":"Statistical Analysis System, Version 6.12","year":"1997"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.2307\/2556170"},{"key":"e_1_2_1_24_2","first-page":"1917","volume-title":"Physician's Desk Reference.","year":"2000"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1999.00903.x"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1177\/107424849800300203"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050678"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F00912700022009611","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/00912700022009611","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T15:35:36Z","timestamp":1698593736000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/00912700022009611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,8]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2000,8]]}},"alternative-id":["10.1177\/00912700022009611"],"URL":"https:\/\/doi.org\/10.1177\/00912700022009611","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,8]]}}}